COVID-19 Coagulopathy: Whom to Anticoagulate and How? What Agents to…

Rush University Medical Center

S. Jain

Role of Anticoagulants and Antiplatelet Agents for Patients With COV…

CHEST 2022 Coverage

V. Balasubramanian

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

How do I Recognize and Treat the VEXAS Syndrome?

Cleveland Clinic Rheumatology

P. Grayson

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

Summary of Recent Updates in MDS

Vanderbilt University Medical Center (VUMC)

S. Ball

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

2024 Updates on Myeloproliferative Neoplasms, PV, and ET

Integrity CE

A. Tefferi

Experts Discuss Pros and Cons of Treatment Approaches in PV

BMFcases

T. Bat, A. Tefferi

2024 Updates in PV/ET

University of Colorado Division of Hematology

B. McMahon

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…

BMFcases

T. Bat, A. Tefferi

Masterclasses from the Wards

Masterclasses in Dermatology

S. Elman

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

UChicago Medicine 12th International Clinical Cancer Genomics Conference

L. Banaszak

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

Ruben Mesa